GOSS - Gossamer Bio Inc Stock Price, Fair Value and News

0.69USD-0.04 (-5.48%)Market Closed

Market Summary

USD0.69-0.04

Market Closed

-5.48%

GOSS Stock Price

View Fullscreen

GOSS RSI Chart

GOSS Valuation

Market Cap

156.1M

Price/Earnings (Trailing)

-0.9

Price/Sales (Trailing)

104.32

Price/Free Cashflow

-0.98

GOSS Price/Sales (Trailing)

GOSS Profitability

Return on Equity

-645.83%

Return on Assets

-66.54%

Free Cashflow Yield

-101.52%

GOSS Fundamentals

GOSS Revenue

Revenue (TTM)

1.6M

GOSS Earnings

Earnings (TTM)

-172.6M

Earnings Growth (Yr)

14.72%

Earnings Growth (Qtr)

12.92%

Breaking Down GOSS Revenue

Last 7 days

-6.8%

Last 30 days

-15.8%

Last 90 days

-36.1%

Trailing 12 Months

-51.4%

How does GOSS drawdown profile look like?

GOSS Financial Health

Current Ratio

7.13

GOSS Investor Care

Shares Dilution (1Y)

137.02%

Diluted EPS (TTM)

-0.93

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	966.5K	1.2M	1.4M	1.6M
2021	2.8M	2.1M	1.4M	761.0K
2020	5.0M	4.5M	4.0M	3.4M
2019	0	0	0	5.6M
2018	0	0	0	1.7M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Gossamer Bio Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 27, 2024	hasnain faheem	sold	-26,772	1.1554	-23,172	president & ceo
Mar 27, 2024	christian waage	sold	-7,429	1.1555	-6,430	evp, tech ops and admin
Mar 27, 2024	giraudo bryan	sold	-7,430	1.1556	-6,430	coo/cfo
Mar 18, 2024	peterson caryn	sold	-5,342	1.3297	-4,018	evp, regulatory affairs
Mar 18, 2024	aranda richard	sold	-5,341	1.3295	-4,018	chief medical officer
Nov 15, 2023	milligan sandra	bought	25,212	0.7879	32,000	-
Nov 13, 2023	giraudo bryan	bought	112,880	0.5644	200,000	coo/cfo
Jul 24, 2023	giraudo bryan	acquired	98,316	1.82	54,020	coo/cfo
Jul 24, 2023	hasnain faheem	acquired	983,120	1.82	540,176	president & ceo
Jul 24, 2023	christian waage	acquired	24,577	1.82	13,504	evp, tech ops and admin

Which funds bought or sold GOSS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 17, 2024	Artal Group S.A.	added	10.37	4,700,580	15,704,600	0.40%
May 16, 2024	JANE STREET GROUP, LLC	added	45.32	177,955	380,350	-%
May 15, 2024	TWINBEECH CAPITAL LP	new	-	50,192	50,192	-%
May 15, 2024	Cetera Investment Advisers	sold off	-100	-9,125	-	-%
May 15, 2024	Cubist Systematic Strategies, LLC	new	-	165,298	165,298	-%
May 15, 2024	ARMISTICE CAPITAL, LLC	sold off	-100	-3,792,350	-	-%
May 15, 2024	Schonfeld Strategic Advisors LLC	reduced	-51.16	-124,255	213,058	-%
May 15, 2024	D. E. Shaw & Co., Inc.	added	16.97	237,074	699,609	-%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-36.9	-1,030,780	4,572,180	-%
May 15, 2024	Samsara BioCapital, LLC	unchanged	-	1,639,850	7,233,720	1.12%

Are Funds Buying or Selling GOSS?

Are funds buying GOSS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own GOSS

No. of Funds

Unveiling Gossamer Bio Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	hillhouse investment management, ltd.	2.2%	4,974,041	SC 13G/A
Feb 13, 2024	vanguard group inc	5.16%	11,635,634	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G
Feb 09, 2024	arch venture fund ix, l.p.	-	0	SC 13G/A
Jan 11, 2024	millennium management llc	1.9%	4,224,610	SC 13G/A
Jan 11, 2024	artal international s.c.a.	5.8%	13,108,880	SC 13G
Jul 28, 2023	growth equity opportunities 18 vge, llc	8.2%	18,793,076	SC 13D
May 10, 2023	state street corp	1.39%	1,319,485	SC 13G/A
May 05, 2023	blackrock inc.	4.9%	4,653,619	SC 13G/A
Feb 14, 2023	hhlr advisors, ltd.	5.3%	4,974,041	SC 13G/A

Recent SEC filings of Gossamer Bio Inc

View All Filings

Date Filed	Form Type	Document
May 07, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
May 06, 2024	8-K	Current Report
Apr 26, 2024	ARS	ARS
Apr 24, 2024	DEF 14A	DEF 14A
Apr 24, 2024	DEFA14A	DEFA14A
Mar 28, 2024	4	Insider Trading
Mar 28, 2024	4	Insider Trading
Mar 28, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading

Peers (Alternatives to Gossamer Bio Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Gossamer Bio Inc News

Latest updates

Gossamer Bio Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2018Q4
Operating Expenses	-3.0%	54,357,000	56,021,000	53,872,000	54,343,000	51,661,000	55,664,000	55,596,000	53,203,000	60,087,000	53,569,000	65,339,000	54,967,000	55,787,500	39,807,000
S&GA Expenses	11.6%	12,834,000	11,497,000	11,277,000	12,001,000	10,714,000	12,459,000	11,263,000	11,346,000	15,877,000	11,448,000	11,655,000	10,748,000	11,591,500	13,935,000
EBITDA Margin	-	-	-	-282	-281	-279	-	-	-65.41	-66.61	-30.55	-31.17	-31.57	-31.90	-85.27
Interest Expenses	-0.5%	3,457,000	3,475,000	3,481,000	3,467,000	4,937,000	4,889,000	4,834,000	4,780,000	4,753,000	4,715,000	2,491,000	707,000	1,084,000	-
EBT Margin	-	-	-	-307	-307	-307	-	-	-70.70	-70.70	-32.41	-32.41	-32.41	-32.41	-85.45
Net Income	6.1%	-55,764,000	-59,363,000	-56,466,000	-57,785,000	-56,284,000	-60,247,000	-59,832,000	-57,641,000	-64,604,000	-57,812,000	-66,870,000	-54,074,000	-54,698,000	-38,794,000
Net Income Margin	13.2%	-144	-166	-196	-242	-307	-169	-114	-	-	-	-	-	-	-
Free Cashflow	-29.2%	-47,832,000	-37,028,000	-48,942,000	-53,640,000	-40,592,000	-42,558,000	-47,588,000	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-16.8%	259	312	348	182	220	272	324	246	295	344	387	433	482	539	584	625	371	427	470	507	516
Current Assets	-16.7%	255	307	341	173	210	262	312	233	281	332	374	417	466	522	566	608	355	409	452	490	498
Cash Equivalents	21.0%	39.00	32.00	83.00	37.00	65.00	112	153	94.00	139	183	214	343	440	487	462	486	111	135	131	149	171
Net PPE	-34.8%	1.00	2.00	2.00	3.00	4.00	4.00	4.00	5.00	5.00	5.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	5.00	5.00	5.00	4.00
Liabilities	-6.6%	233	249	243	245	248	260	267	262	265	222	217	212	210	219	212	205	65.00	74.00	71.00	66.00	36.00
Current Liabilities	-30.6%	36.00	52.00	42.00	40.00	41.00	49.00	53.00	44.00	35.00	40.00	36.00	30.00	29.00	39.00	33.00	28.00	28.00	37.00	33.00	28.00	25.00
Long Term Debt	-100.0%	-	1.00	4.00	6.00	9.00	12.00	15.00	18.00	29.00	29.00	29.00	29.00	29.00	29.00	29.00	29.00	29.00	28.00	28.00	28.00	-
LT Debt, Current	-17.4%	10.00	12.00	12.00	12.00	12.00	12.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	1.00	4.00	6.00	9.00	12.00	15.00	18.00	29.00	29.00	29.00	29.00	29.00	29.00	29.00	29.00	29.00	28.00	28.00	28.00	-
Shareholder's Equity	-57.4%	27.00	63.00	105	-	-28.46	12.00	56.00	-	30.00	121	170	221	272	321	372	420	306	352	399	441	480
Retained Earnings	-3.5%	-1,254	-1,212	-1,163	-1,123	-1,081	-1,032	-976	-917	-860	-811	-755	-695	-635	-577	-512	-455	-388	-334	-279	-230	-186
Additional Paid-In Capital	0.5%	1,281	1,275	1,269	1,062	1,053	1,045	1,033	901	891	933	925	915	907	898	885	875	695	686	678	672	667
Shares Outstanding	0.4%	226	225	225	95.00	95.00	94.00	91.00	77.00	76.00	75.00	75.00	75.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	98.00	-	-	-	541	-	-	-	517	-	-	-	775	-	-	-	948	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-56.5%	-52,302	-33,424	-34,494	-38,251	-52,989	-47,730	-36,997	-48,822	-53,483	-40,509	-42,035	-47,450	-58,896	-36,736	-44,930	-42,399	-52,295	-44,140	-36,110	-36,810	-27,774
Share Based Compensation	-3.7%	5,811	6,032	6,162	8,197	8,127	11,449	10,122	9,999	10,983	7,659	7,587	8,054	8,708	12,681	8,923	8,900	8,244	6,862	5,728	5,140	3,089
Cashflow From Investing	529.3%	61,673	-14,366	-118,262	12,936	8,722	8,464	-22,598	4,679	8,420	10,443	-89,762	-50,076	11,968	61,100	19,959	106,245	28,038	46,933	17,949	-13,884	-198,142
Cashflow From Financing	12.0%	-2,555	-2,903	198,497	-2,904	-2,536	-2,873	119,221	21.00	721	371	1,913	271	774	249	891	310,829	571	1,518	369	28,347	291,344

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

GOSS Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 32,392	$ 37,795
In process research and development	0	15
General and administrative	9,567	10,132
Total operating expenses	41,959	47,942
Loss from operations	(41,959)	(47,942)
Other income (expense)
Interest income	344	587
Interest expense	(3,129)	(3,500)
Other income, net	2,816	1,690
Total other income (expense), net	31	(1,223)
Net loss	(41,928)	(49,165)
Other comprehensive income (loss):
Foreign currency translation	(119)	23
Unrealized gain (loss) on marketable securities	(159)	115
Other comprehensive income (loss)	(278)	138
Comprehensive loss	$ (42,206)	$ (49,027)
Net loss per share, basic (in dollars per share)	$ (0.19)	$ (0.52)
Net loss per share, diluted (in dollars per share)	$ (0.19)	$ (0.52)
Weighted average common shares outstanding, basic (in shares)	225,735,236	94,870,293
Weighted average common shares outstanding, diluted (in shares)	225,735,236	94,870,293

GOSS Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 38,863	$ 32,109
Marketable securities	205,531	264,316
Prepaid expenses and other current assets	10,875	10,094
Total current assets	255,269	306,519
Property and equipment, net	1,074	1,648
Operating lease right-of-use assets	2,404	3,131
Other assets	613	618
Total assets	259,360	311,916
Current liabilities
Accounts payable	2,660	5,526
Accrued research and development expenses	8,929	7,779
Current portion of long-term debt	9,589	11,613
Accrued expenses and other current liabilities	14,641	26,680
Total current liabilities	35,819	51,598
Long-term convertible senior notes	196,819	196,591
Long-term debt	0	814
Operating lease liabilities - long-term	0	144
Total liabilities	232,638	249,147
Commitments and contingencies (Note 9)
Stockholders' equity
Common stock, $0.0001 par value; 700,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 226,218,653 shares issued and outstanding as of March 31, 2024, and 225,409,315 shares issued and outstanding as of December 31, 2023	23	23
Additional paid-in capital	1,281,295	1,275,136
Accumulated deficit	(1,253,968)	(1,212,040)
Accumulated other comprehensive loss	(628)	(350)
Total stockholders' equity	26,722	62,769
Total liabilities and stockholders' equity	$ 259,360	$ 311,916

About Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

CEO	Mr. Faheem Hasnain
WEBSITE	gossamerbio.com
INDUSTRY	Biotechnology
EMPLOYEES	178

Gossamer Bio Inc Frequently Asked Questions

What is the ticker symbol for Gossamer Bio Inc? What does GOSS stand for in stocks?

GOSS is the stock ticker symbol of Gossamer Bio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Gossamer Bio Inc (GOSS)?

As of Fri May 17 2024, market cap of Gossamer Bio Inc is 156.09 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GOSS stock?

You can check GOSS's fair value in chart for subscribers.

What is the fair value of GOSS stock?

You can check GOSS's fair value in chart for subscribers. The fair value of Gossamer Bio Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Gossamer Bio Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for GOSS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Gossamer Bio Inc a good stock to buy?

The fair value guage provides a quick view whether GOSS is over valued or under valued. Whether Gossamer Bio Inc is cheap or expensive depends on the assumptions which impact Gossamer Bio Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GOSS.

What is Gossamer Bio Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, GOSS's PE ratio (Price to Earnings) is -0.9 and Price to Sales (PS) ratio is 104.32. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GOSS PE ratio will change depending on the future growth rate expectations of investors.